Evidence map›Paper›PMID 36157585›Full record

ArticleiScience2022

Cannabidiol counters the effects of a dominant-negative pathogenic Kv7.2 variant.

Xiaoqin Zhan, Chris Drummond-Main, Dylan Greening, Jinjing Yao, S W R Chen, J P Appendino, P Y Billie Au, Ray W Turner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Evaluation of Small-Molecule Candidates as Modulators of M-Type KInternational journal of molecular sciences · 2025
    Review
  3. Cannabidiol Modulates M-Type KBiomedicines · 2023
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoqin ZhanAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Chris Drummond-MainHotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Dylan GreeningHotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Jinjing YaoLibin Cardiovascular Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
S W R ChenLibin Cardiovascular Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
J P AppendinoAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
P Y Billie AuAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Ray W TurnerAlberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy and neurodevelopmental disorders can arise from pathogenic variants of KCNQ (Kv7) channels. A patient with developmental and epileptic encephalopathy exhibited an in-frame deletion of histidine 260 on Kv7.2. Coexpression of Kv7.2 mutant (mut) subunits with Kv7.3 invoked a decrease in current density, a depolarizing shift in voltage for activation, and a decrease in membrane conductance. Biotinylation revealed an increased level of surface Kv7.2mut compared to Kv7.3 with no change in total membrane protein expression. Super-resolution and FRET imaging confirmed heteromeric channel formation and a higher expression density of Kv7.2mut. Cannabidiol (1 μM) offset the effects of Kv7.2mut by inducing a hyperpolarizing shift in voltage for activation independent of CB1 or CB2 receptors. These data reveal that the ability for cannabidiol to reduce the effects of a pathogenic Kv7.2 variant supports its use as a potential therapeutic to reduce seizure activity.

Indexed as

Biological sciencesHealth sciencesNeuroscience

Identifiers

PMID36157585
PMCPMC9490039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.